“We definitely do see a slight change compared to the total population, we do see a slight pullback in overall basket,” Walmart U.S. CEO John Furner told the publication. “Just less units, slightly less calories.”
According to the report, Walmart and some food manufacturers are studying how weight loss drugs are affecting consumer behaviors and shopping habits.
Despite the slight decline in food purchases, Walmart executives have said recently that total food, consumables, and health and wellness purchases are still expected to increase percentage-wise through the end of this year, and that individuals taking GLP-1s are more likely to spend more with the retailer on other products.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.